VICO Vicore Pharma Holding AB (publ)

1.008USD10.24 SEK · STO-0.39%Mkt Cap: 283.87M USDP/E: —

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule…

Key Statistics

Company
Market Cap283.87M USD
Enterprise Value207.89M USD
Revenue (TTM)376.79K USD
Gross Profit375.71K USD
Net Income (TTM)-47.00M USD
Revenue/Share0.0014 USD
Last Price1.008 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees50
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0007577895
Valuation
P/E (Trailing)—
P/E (Forward)-5.33
PEG—
EV/EBITDA—
EV/Revenue551.74
P/S753.41
P/B3.98
EPS (TTM)-0.19 USD
EPS (Forward)-0.19 USD
52W Range
0.842617% of range1.795
52W High1.795 USD
52W Low0.8426 USD
Profitability
Gross Margin100.00%
Oper. Margin-14442.84%
EBITDA Margin0.00%
Profit Margin-12509.14%
ROE-43.59%
ROA-39.18%
ROIC—
ROCE-41.31%
Growth
Revenue Growth-21.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.98M USD
CapEx (TTM)—
FCF Margin-7936.60%
FCF Yield-10.53%
Net Debt-75.99M USD
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio8.88
Quick Ratio8.52
Book Value/Sh0.25 USD
Cash/Share0.27 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.608 USD
Upside (mean)+158.8%
Target Range1.476 USD – 3.839 USD
1.476+158.8% to mean3.839
# Analysts7
Ownership
Shares Out.281.64M
Float200.92M
Insiders13.27%
Institutions58.35%
Technical
SMA 500.9564 (+5.4%)
SMA 2001.044 (-3.4%)
Beta0.10
S&P 52W Chg12.00%
Avg Vol (30d)1.52M
Avg Vol (10d)1.68M
Technical Indicators
RSI (14)53.2
MACD0.2745
MACD Signal0.2656
MACD Hist.+0.0089
BB Upper1.120 USD
BB Middle0.9934 USD
BB Lower0.8668 USD
BB Width25.48%
ATR (14)0.0468 USD
Vol Ratio (20d)0.42x

About Vicore Pharma Holding (STO: VICO)

›

Vicore Pharma Holding (STO: VICO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 50 employees.

The shares were at 10.24 SEK on 19 November 2026, roughly unchanged over 52 weeks. Its 52-week range is 8.560 SEK to 18.24 SEK: the price is 43.9% below the high and 19.6% above the low.

Its market capitalisation is 2.88B SEK.

Vicore Pharma Holding reports return on equity of -43.6% and revenue down 21.8% year over year.

It holds more cash than debt, a net cash position of 771.99M SEK. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 26.50 SEK is 158.8% above the current price. The next earnings report is expected on 25 February 2027.